CP-481,715 Nickel Allergy Study.

Dermatitis, Allergic Contact Clinical Trial

Official title:
Placebo-Controlled, Randomized, Parallel Group, Multiple-Dose Study to Evaluate the Effects of CP-481,715 on Clinical Response and Cellular Infiltration Following Contact Allergen Challenge to the Skin of Nickel Allergic Subjects.

Status Completed

Clinical Trial Summary

To evaluate the suitability of contact allergy as a method for the evaluation of c-chemokine receptor-1 antagonist.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Dermatitis, Allergic Contact

Clinical Trial Details

NCT number	NCT00141180
Study type	Interventional
Source	Pfizer
Contact
Status	Completed
Phase	Phase 1
Start date	September 2003
Completion date	October 2005

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01953380` - Intervention Study to Evaluate the Importance of Information Given to Patients With Contact Allergy	N/A
Completed	`NCT00928447` - Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis	Phase 2
Completed	`NCT04182425` - Incidence of Allergic Manifestations and Infectious Episodes in Healthy Term Infants at Risk for Dysbiosis
Terminated	`NCT02483728` - Cutaneous and Systemic Reactions to Metal Implants	N/A
Completed	`NCT03522675` - NeoMatriX Wound Matrix Collagen Dressing Skin Prick Test	N/A